Teriflunomide

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Teriflunomide
   1. Pharmacist Assessment Report
   2. Teriflunomide: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Teriflunomide: Known uses and market status in Canada

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Teriflunomide, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is relapsing-remitting multiple sclerosis, which is supported by a licence in another country.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 7 of 8; cancelled: 1)
Number of DINs	8 (marketed: 7)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
relapsing-remitting multiple sclerosis	licence in another country (approved indication: multiple sclerosis)

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02500310	NAT-TERIFLUNOMIDE		Valid
02505843	SANDOZ TERIFLUNOMIDE		Valid
02523833	M-TERIFLUNOMIDE		Valid
02501090	TEVA-TERIFLUNOMIDE		Valid
02500434	PMS-TERIFLUNOMIDE		Valid
02500469	MAR-TERIFLUNOMIDE		CANCELLED POST MARKET
02500639	APO-TERIFLUNOMIDE		Valid
02504170	JAMP TERIFLUNOMIDE		Valid

Safety Considerations

Drug Interactions: The interaction screening returned 100 interacting drugs; the most prominent are listed below.

• Major: acarbose, hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide, pioglitazone, bupropion, acetylsalicylic acid, chenodeoxycholic acid, clarithromycin, minocycline, oxandrolone, oxymetholone
• Moderate: alosetron, cimetidine, empagliflozin, sitagliptin
• Minor: zinc sulfate, zinc acetate

For warnings and contraindications, please refer to the package insert.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---